Articles from Stuart Therapeutics, Inc.

Stuart Therapeutics, Inc. (“Stuart”), a late-stage biopharmaceutical company developing a new class of therapeutics designed to repair helical collagen for the treatment of eye diseases, today announced that Eric Schlumpf, President and CEO of Stuart Therapeutics, will participate in a fireside chat discussion at the Citizens Private Ophthalmology Summit on Thursday, September 17, 2026, at 2 p.m. EDT. The Summit will showcase innovation in ophthalmology with presentations and management discussions involving companies developing therapeutic candidates for both back and front of the eye across a variety of modalities, including facilitated perspectives from select key opinion leaders.

Stuart Therapeutics, Inc. (“Stuart”), a late-stage biopharmaceutical company developing first-in-class collagen-reparative therapeutics to treat eye diseases, today announced the appointment of Dave LeCause as senior commercial advisor. LeCause will lead the company's commercial strategy as Stuart advances its lead therapeutic candidate, ST-100 for dry eye disease. ST-100 is expected to begin Phase 3b clinical trials in the first quarter of 2027.

Stuart Therapeutics, Inc. (“Stuart”), a clinical-stage biopharmaceutical company developing first-in-class collagen-reparative therapeutics to treat eye diseases, today announced the appointment of David Jakeman as chief financial officer. Jakeman will lead the company's finance and accounting operations as Stuart advances its lead candidate, ST-100 for dry eye disease, through completion of its pending Phase 3b clinical trial and into preparations for commercialization.